SARS-CoV-2 Antibody responses in end-stage renal disease patients after COVID-19 Vaccination

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210510009

Enrollment

Registered

2021-05-10

Start date

2021-05-17

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease patients with renal replacement therapy receiving COVID-19 vaccine ESRD End stage kidney disease COVID-19 SARS-CoV-2 Vaccine RRT Renal replacement therapy

Interventions

End stage renal disease patients with renal replacement therapy who receive COVID-19 vaccine

Prevention

ESRD

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or more 2. End stage renal disease patients with renal replacement therapy visiting out-patient department 3. Eligible for COVID-19 vaccination 4. Informed consented for participation

Exclusion criteria

Exclusion criteria: 1. Allergy to component in COVID-19 vaccine 2. Diagnosed with COVID-19 infection 3. Contraindicated for COVID-19 vaccine 4. On immunosuppressant

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 Antibody Before vaccination (Day 0), 5 and 10 weeks after first dose vaccination, 5 and 10 weeks after second dose vaccination ELISA, In vitro microneutralization assay, Rapid IgG/IgM Antibody Test Kit	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactWisit Prasitsirikul

Bamrasnaradura Infectious Diseases Institute

drwisit_p@yahoo.com029511170

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026